Friday, 24th November 2017
news Got a story? We pay $$$ |Email:editor@zimdaily.com

Zacks: Biotie Therapies Oyj (NASDAQ:BITI) given $28.00 consensus price target …

Zacks: Biotie Therapies Oyj (NASDAQ:BITI) given $28.00 consensus price target …

By
Published: 21 December 2015

ZIMBABWE – Biotie Therapies Oyj (NASDAQ:BITI) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $28.00 for the company and are anticipating that the company will post ($0.87) EPS for the current quarter, according to Zacks. Zacks has also assigned Biotie Therapies Oyj an industry rank of 54 out of 265 based on the ratings given to related companies.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research cut Biotie Therapies Oyj from a “hold” rating to a “sell” rating in a research note on Tuesday, September 15th. RBC Capital reiterated an “outperform” rating and set a $35.00 price objective on shares of Biotie Therapies Oyj in a research note on Monday, September 28th.

Biotie Therapies Oyj (NASDAQ:BITI) opened at 14.00 on Tuesday. The company’s market capitalization is $171.64 million. Biotie Therapies Oyj has a 12 month low of $12.43 and a 12 month high of $25.39. The company has a 50-day moving average price of $13.82 and a 200 day moving average price of $16.41.

Biotie Therapies Oyj is a Finland-based drug development company focused on developing products for neurodegenerative and psychiatric disorders. The Company’s lead market product is Selincro (NASDAQ:BITI), a therapeutic for alcohol dependence that is rolled out across Europe by its partner Lundbeck. Its product pipeline includes tozadenant, a therapeutic for Parkinson’s disease that is in Phase Three development; and two additional compounds in Phase Two development that treat cognitive disorders, namely: SYN120, an orally administered compound therapeutic for Parkinson’s disease dementia, and BTT1023, a human monoclonal antibody targeting compound therapeutic for primary sclerosing cholangitis. The Company operates as a subsidiary of Biotie Therapies Corp.